Autoimmune conditions show evidence of imbalances in the little known or understood endocannabinoid system (ECS). This master regulator of neurotransmission, metabolism and hormone systems is regarded as the “gate keeper” for immune function with the express purpose of maintaining a balance between acute activation and self recognition. Dysregulation of the ECS is closely correlated in almost all autoimmune conditions with multiple sclerosis being the best studied to date. ECS targets using phytocannabinoids have been partially successful with Sativex for spastic symptoms.
Cannabidiol, a component of Sativex, has immuno-modulating effects independent of THC but without psychoactive effects. Cannabidiol (CBD) has pleiotrophic effects on immune cell types in all organ systems from the epidermis to the glia
of the brain. In preclinical studies CBD has been shown to modulate cytokines, immune cell type, migration and populations, vascular changes and pain. Despite this breadth of action no toxicity, significant adverse effects or immune compromise have been identified. Furthermore, CBD appears to have immediate restorative effects for anxiety, mood, and sleep. This presentation will review the evidence, products and dosing recommendations for CBD for autoimmune disorders in conjunction with other lifestyle and dietary changes.